


PRODUCT INFORMATION



Cinacalcet-d₃ (hydrochloride) Item No. 25036

CAS Registry No.: 2749807-20-1
Formal Name: (αR)-α-(methyl-d₃)-N-[3-[3-(trifluoromethyl)phenyl]propyl]-1-naphthalenemethanamine, monohydrochloride
Synonym: AMG 073-d₃
MF: C₂₂H₁₉D₃F₃N • HCl
FW: 396.9
Chemical Purity: ≥98% (Cinacalcet)
Deuterium Incorporation: ≥99% deuterated forms (d₁-d₃); ≤1% d₀
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Cinacalcet-d₃ (hydrochloride) is intended for use as an internal standard for the quantification of cinacalcet (Item No. 16042) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated *versus* unlabeled).

Cinacalcet-d₃ (hydrochloride) is supplied as a solid. A stock solution may be made by dissolving the cinacalcet-d₃ (hydrochloride) in the solvent of choice, which should be purged with an inert gas. Cinacalcet-d₃ (hydrochloride) is soluble in organic solvents such as ethanol, methanol, DMSO, and dimethyl formamide.

Description

Cinacalcet is a calcimimetic and an allosteric agonist of the calcium-sensing receptor (CaSR; EC₅₀ = 79.4 nM in HEK293T cells expressing the human receptor).¹ *In vivo*, cinacalcet (0.1-10 mg/kg, s.c.) decreases plasma levels of parathyroid hormone (PTH) in rats. It also decreases plasma levels of PTH and parathyroid cell proliferation in a mouse model of primary hyperparathyroidism.² Formulations containing cinacalcet have been used in the treatment of secondary hyperparathyroidism due to end-stage renal disease and hypercalcemia in patients with parathyroid carcinoma.

References

1. Ma, J.N., Owens, M., Gustafsson, M., *et al.* Characterization of highly efficacious allosteric agonists of the human calcium-sensing receptor. *J. Pharmacol. Exp. Ther.* 337(1), 275-284 (2011).
2. Imanishi, Y., Kawata, T., Kenko, T., *et al.* Cinacalcet HCl suppresses *Cyclin D1* oncogene-derived parathyroid cell proliferation in a murine model for primary hyperparathyroidism. *Calcif. Tissue Int.* 89(1), 29-35 (2011).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 01/09/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM